Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study
Xevinapant联合avelumab治疗晚期实体瘤，并在晚期非小细胞肺癌中进行剂量扩展：一项开放标签、非随机Ib期研究的探索性生物标志物、安全性和疗效分析
期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359251332154
Goss, Glenwood; Ciuleanu, Tudor; Ramlau, Rodryg; Renouf, Daniel J; Chu, Quincy; Kalinka, Ewa; Sawrycki, Piotr; Bramson, Jonathan; Nelson, Brad H; Crabbé, Rafael; LaCasse, Eric; Lo, Bryan; Sahlender, Daniela A; Crompton, Philippa; Brichory, Franck; Piggott, Luke; Schenker, Michael; Juergens, Rosalyn
